COPYRIGHT © DIGITAL JOURNAL INC. Sitemaps: XML / News. Digital Journal is not responsible for the content of external sites. Read more about our external linking
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Influenza pipeline constitutes key companies continuously working towards developing Influenza treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
“Influenza Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Influenza Market.
The Influenza Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Influenza Pipeline Report:
• Companies across the globe are diligently working toward developing novel Influenza treatment therapies with a considerable amount of success over the years.
• Influenza companies working in the treatment market are Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc., GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Pneumagen Ltd., Ena Respiratory, Moderna, Inc., Valenta Pharmaceuticals, Raynovent Co., Ltd, and others, are developing therapies for the Influenza treatment
• Emerging Influenza therapies such as – LUNAR-FLU, naNO-Flu, UniFlu, CC-42344, GSK4382276A, CVSQIV, ALVR 106, mRNA-1073, OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others are expected to have a significant impact on the Influenza market in the coming years.
• In June 2022, Moderna initiated Phase III randomized, observer-blind study is designed to evaluate the safety and immunological non-inferiority of mRNA-1010 to a licensed seasonal influenza vaccine in adults 18 years and older. Participants will be randomly assigned on a 1:1 ratio to receive either a single dose of mRNA-1010 or a single dose of a licensed seasonal influenza vaccine as a comparator
• In June 2022, Moderna, Inc. announced that the first participants have been dosed in a Phase III study of the Company’s seasonal influenza vaccine candidate (mRNA-1010). The trial is expected to enroll approximately 6,000 adults in Southern Hemisphere countries
Influenza Overview
Influenza is a communicable viral disease that affects the upper respiratory tract, including upper and lower respiratory passages. A wide spectrum of influenza viruses causes it. Some of these viruses can infect humans, and some are specific to different species.
Get a Free Sample PDF Report to know more about Influenza Pipeline Therapeutic Assessment
Emerging Influenza Drugs Under Different Phases of Clinical Development Include:
• LUNAR-FLU: Arcturus Therapeutics
• naNO-Flu: Emergex Vaccines
• UniFlu: Emergent Biosolutions
• CC-42344: Cocrystal Pharma Inc.
• GSK4382276A: GlaxoSmithKline
• CVSQIV: CureVac AG
• ALVR 106: AlloVir
• mRNA-1073: Moderna
• OVX836: OSIVAX
• Neumifil: Pneumagen Ltd.
• INNA-051: Ena Respiratory
• mRNA-1010: Moderna, Inc.
• XC-221: Valenta Pharmaceuticals
• ZSP1273: Raynovent Co., Ltd
Route of Administration
Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous
Molecule Type
Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine
Influenza Pipeline Therapeutics Assessment
• Influenza Assessment by Product Type
• Influenza By Stage and Product Type
• Influenza Assessment by Route of Administration
• Influenza By Stage and Route of Administration
• Influenza Assessment by Molecule Type
• Influenza by Stage and Molecule Type
DelveInsight’s Influenza Report covers around products under different phases of clinical development like-
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Influenza product details are provided in the report. Download the Influenza pipeline report to learn more about the emerging Influenza therapies
Some of the key companies in the Influenza Therapeutics Market include:
Key companies developing therapies for Influenza are – Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Cidara Therapeutics, Inc., Medicago, Sanofi, Translate Bio, Arcturus Therapeutics, Inc., BiondVax Pharmaceuticals, Adagio Therapeutics, Virpax Pharmaceuticals, Blue Water Vaccines, SINOVAC, PDS Biotechnology, Pneumagen, Abivax, Seqirus, ExpreS2ion Biotechnologies, Vivaldi Biosciences, Ethris, GC Biopharma, AIM ImmunoTech, Eyam Vaccines And Immunotherapeutics, SyneuRx, and others.
Influenza Pipeline Analysis:
The Influenza pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Influenza with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Influenza Treatment.
• Influenza key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Influenza Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Influenza market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Influenza drugs and therapies
Influenza Pipeline Market Drivers
• Increasing awareness by government authorities, increasing clinical trials for new product development, increase in investment by leading market players, are some of the important factors that are fueling the Influenza Market.
Influenza Pipeline Market Barriers
• However, Longer process for novel vaccine development, high cost of vaccine development and other factors are creating obstacles in the Influenza Market growth.
Scope of Influenza Pipeline Drug Insight
• Coverage: Global
• Key Influenza Companies: Arcturus Therapeutics, Emergex Vaccines, Emergent Biosolutions, Cocrystal Pharma Inc., GlaxoSmithKline, CureVac AG, AlloVir, Moderna, OSIVAX, Pneumagen Ltd., Ena Respiratory, Moderna, Inc., Valenta Pharmaceuticals, Raynovent Co., Ltd, and others
• Key Influenza Therapies: LUNAR-FLU, naNO-Flu, UniFlu, CC-42344, GSK4382276A, CVSQIV, ALVR 106, mRNA-1073, OVX836, Neumifil, INNA-051, mRNA-1010, XC-221, ZSP1273, and others
• Influenza Therapeutic Assessment: Influenza current marketed and Influenza emerging therapies
• Influenza Market Dynamics: Influenza market drivers and Influenza market barriers
Request for Sample PDF Report for Influenza Pipeline Assessment and clinical trials
Table of Contents
1 Influenza Report Introduction
2 Influenza Executive Summary
3 Influenza Overview
4 Influenza- Analytical Perspective In-depth Commercial Assessment
5 Influenza Pipeline Therapeutics
6 Influenza Late Stage Products (Phase II/III)
7 Influenza Mid Stage Products (Phase II)
8 Influenza Early Stage Products (Phase I)
9 Influenza Preclinical Stage Products
10 Influenza Therapeutics Assessment
11 Influenza Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Influenza Key Companies
14 Influenza Key Products
15 Influenza Unmet Needs
16 Influenza Market Drivers and Barriers
17 Influenza Future Perspectives and Conclusion
18 Influenza Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Related Reports by DelveInsight-
scedosporium infection market | autoimmune pulmonary alveolar proteinosis market | rosai-dorfman disease market | sandhoff disease market | b-cell chronic lymphocytic leukemia market | bladder cancer market | trichomoniasis market | bile duct cancer market | resorbable vascular scaffold market | salivary gland infection market | ischemic stroke market | paget’s disease market | ventricular assist devices market | vascular stents market | vascular graft devices market | bladder scanners market | b-cell non-hodgkin lymphoma market | basal cell carcinoma market | birch allergy market | vein illumination devices market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting